Table 1 |
||
|
General and disease characteristics as well as endothelial function scores for patients in the cross-sectional study |
||
|
RA patients |
Number |
|
|
|
||
|
General characteristics |
||
|
Sex female n (%) |
72 (73) |
99 |
|
Disease characteristics |
||
|
RF positive n (%) |
70 (78) |
90 |
|
Disease duration (years) |
11 ± 10 |
74 |
|
ESR (mm/hr) |
17.0 (8.8-28.3) |
90 |
|
CRP (mg/L) |
5.0 (2.9-13.50) |
93 |
|
DAS28 |
3.6 ± 1.3 |
93 |
|
HAQ |
1.7 ± .87 |
95 |
|
RA medications |
||
|
Methotrexate n (%) |
60 (60) |
99 |
|
Prednisolone n (%) |
22 (22) |
99 |
|
NSAIDS n (%) |
18 (18) |
99 |
|
Cyclooxygenase II inhibitors n (%) |
11 (11) |
99 |
|
Anti-TNF-α therapy n (%) |
11 (11) |
99 |
|
CVD medications |
||
|
Antihypertensive n (%) |
25 (25) |
99 |
|
Antihypercholesterolemic n (%) |
12 (12) |
99 |
|
Beta-blocker n (%) |
7 (7) |
99 |
|
Calcium channel blocker n (%) |
5 (5) |
99 |
|
Microvascular function |
||
|
Endothelium-dependent (ACh%) |
236 (152-407) |
94 |
|
Endothelium-independent (SNP%) |
261 (181-384) |
94 |
|
Macrovascular function |
||
|
Endothelium-dependent (FMD%) |
9.5 (4.8-13.5) |
96 |
|
Endothelium-independent (GTN%) |
24.0 (16.3-30.4) |
93 |
|
|
||
|
Results are expressed as number (percentage), mean ± SD, or median (25th to 75th) percentile, as appropriate. Ach, acetylcholine; CRP, C-reactive protein; CVD, cardiovascular disease; DAS28, disease activity score in 28 joints; ESR, erythrocyte sedimentation rate; FMD, flow-mediated dilatation; GTN, glyceryl trinitrate; HAQ, Health Assessment Questionnaire, NSAID, nonsteroidal antiinflammatory drug; RA, rheumatoid arthritis; RF, rheumatoid factor; TNF, tumor necrosis factor; SNP, sodium nitroprusside. |
||
|
Sandoo et al. Arthritis Research & Therapy 2012 14:R117 doi:10.1186/ar3847 |
||
